Genicular artery embolization (GAE) is a minimally invasive treatment that has been shown to significantly reduce knee osteoarthritis pain and improve function in selected patients. A physician guides a thin catheter into selected arteries around the knee and delivers tiny particles to reduce blood flow through abnormal vessels associated with inflammation. Clinical trial evidence; Systematic review of clinical outcomes.
International expert recommendations support considering GAE when knee osteoarthritis symptoms persist despite conservative treatment, including for people who cannot undergo or wish to defer knee replacement. GAE provides an additional treatment option between conservative care and surgery. The sections below explain its benefits, patient selection, procedure, recovery, and research findings. International expert consensus.
What is osteoarthritis, and why does it cause knee pain?
Osteoarthritis is a chronic joint disease involving breakdown of the smooth cartilage that cushions the ends of bones, changes in the underlying bone, and inflammation of the joint lining, called the synovium. Inflammatory signals can stimulate new blood vessels to grow within inflamed tissue, a process called angiogenesis. These abnormal vessel networks, or neovascular beds, can help sustain inflammation and may be accompanied by growth of pain-sensing nerves. Inflammatory chemicals can also make nerves more sensitive, contributing to pain during everyday movement. This interaction between inflammation, new blood vessels, and sensitive nerves is one contributor to osteoarthritis pain and helps explain why GAE targets abnormal vessels around the knee. Osteoarthritis overview; Blood vessel and nerve growth; Pain mechanisms.
What is genicular artery embolization?
The genicular arteries form part of the blood-vessel network supplying the knee. Embolization means deliberately reducing or blocking flow in selected vessels. For osteoarthritis, the treatment targets abnormal small vessels supplying inflamed tissue while aiming to preserve circulation to healthy structures. GAE technique and treatment planning.
Also called knee embolization, GAE treats arthritis-related symptoms while preserving the existing knee joint. It uses a small skin opening and does not require opening the joint or replacing its surfaces. Its role is pain relief and improved function; it does not replace lost cartilage, repair a torn meniscus, or correct a major joint deformity. Long-term effects on arthritis progression remain under study. International expert consensus on knee embolization.
How does GAE work for knee arthritis?
Osteoarthritis affects the whole joint. Alongside cartilage loss and changes in underlying bone, the synovium—the lining inside the joint—can become inflamed. This inflammation is called synovitis. Research on human tissue has linked synovial inflammation with the growth of new blood vessels. Research on angiogenesis in osteoarthritis.
Sensory nerves can grow alongside vascular channels, and osteoarthritic tissue can express substances involved in nerve growth. This relationship between abnormal vessels, inflammation, and pain-sensitive nerves provides a biological rationale for GAE. Research on blood vessels and sensory nerve growth.
During GAE, imaging helps the physician identify increased vascularity, sometimes described as an abnormal vascular “blush.” Embolic particles reduce perfusion in this network to address inflammatory knee pain. The physician carefully selects treatment targets to protect blood flow to skin, nerves, and other healthy tissue. GAE targeting and technique.
What does imaging show about inflammation?
Prospective imaging studies have documented reduced synovitis after GAE, supporting its anti-inflammatory rationale. Findings are not uniform: a sham-controlled trial found no significant treatment-related improvement in MRI synovitis at one and four months, with clinical follow-up continuing to 12 months. Research is refining how vascular and inflammatory changes relate to pain relief. Prospective imaging study; Randomized trial with MRI follow-up.
Who is a candidate for GAE?
GAE is a treatment option for people whose knee osteoarthritis pain continues to limit walking, stairs, work, or other daily activities despite conservative care. A specialist assesses:
- A confirmed diagnosis: Symptoms, examination, and imaging should support osteoarthritis as an important source of pain.
- An adequate trial of other care: Exercise or physical therapy, appropriate medication, weight management when relevant, and sometimes injections have not provided sufficient relief.
- Treatment goals: The patient wants another nonsurgical option, is deferring replacement, or has reasons surgery may be unsuitable.
- Procedural suitability: Arterial anatomy, circulation, kidney function, bleeding risk, and other health conditions allow treatment to be considered safely.
Pain severity, symptom duration, and previous treatment help guide selection. A 2026 expert consensus proposed considering GAE for pain of at least 5 out of 10 persisting for at least three months despite conservative treatment. Your physician applies these criteria alongside your individual diagnosis and health needs. 2026 patient-selection consensus.
Age, sex, and body weight
Published populations generally include middle-aged and older adults, often with overweight or obesity. In a 333-patient study, the median age was approximately 68, 55% were women, and median body mass index was 30.5. These figures describe that study’s population; they are not eligibility requirements. Large clinical cohort in Radiology.
Candidacy is individualized across age and body-weight groups. The physician considers your diagnosis, previous treatment, circulation, and overall health rather than relying on age or BMI alone. Patient-selection consensus.
Can GAE help advanced or “bone-on-bone” arthritis?
GAE can be considered for selected patients with advanced arthritis, particularly when knee replacement is unsuitable or being deferred. A 236-patient retrospective study found greater likelihood of success with lower radiographic severity. For severe “bone-on-bone” disease, evaluation focuses on how much pain comes from inflammation versus structural damage or major deformity. Study of factors associated with treatment response; Clinical selection guidance.
MRI can help identify additional contributors to knee pain and guide realistic treatment goals. A small study associated larger bone-marrow lesions and more severe meniscal injury with poorer outcomes. These findings help the physician discuss expected benefit and select the most appropriate treatment. MRI findings and clinical outcomes.
When GAE may be unsuitable
Significant peripheral arterial disease, active infection, severe kidney impairment, contrast-related concerns, or uncorrected clotting problems may prevent treatment or require additional assessment. Arteries around the knee can provide important alternate routes for blood reaching the lower leg. Blocking them may be unsafe when circulation is already compromised. Technical review of patient selection; GENESIS eligibility criteria.
The assessment also identifies other causes of knee pain and helps match treatment to your joint structure, circulation, and overall health.
How to prepare for genicular artery embolization
The team reviews your symptoms, previous treatment, examination, and knee imaging. X-rays help assess arthritis; MRI may clarify structural injury or another diagnosis. Blood tests may assess kidney function, blood counts, and clotting. Tell the team about all medicines, supplements, allergies, previous contrast reactions, and any possibility of pregnancy. GAE preparation and workup; General embolization preparation.
Ask for written instructions about eating, drinking, medication adjustments, and transport home. Do not independently stop prescribed blood thinners. If sedation is planned, arrange an escort and follow the team’s instructions about driving and supervision afterward. Preparing for catheter embolization.
Before treatment, agree on what improvement would mean for you: less pain on stairs, longer walking distance, better sleep, or another specific activity. Recording baseline symptoms makes follow-up more useful.
What happens during a GAE procedure?
1. Monitoring and arterial access
The team monitors your circulation and breathing. The physician can access an artery through the foot (pedal access) or groin (femoral access), depending on your anatomy and the planned approach. Local anesthetic numbs the chosen access site; sedation may also be used. A small access tube allows the physician to introduce a catheter into the artery. Joint embolization procedure; Foot and groin access research.
2. Mapping the arteries around the knee
Contrast material and X-ray imaging show the vessel pattern. A smaller tube called a microcatheter is advanced into selected branches. The physician checks whether abnormal vascularity corresponds to the painful region and looks for connections that could carry particles into healthy tissue. Selective embolization technique.
3. Delivering the embolic particles
Particles are injected under imaging guidance to reduce the abnormal vascular blush. Studies have used permanent particles and temporary or resorbable agents. The physician selects an embolic material and technique according to the treatment plan, vascular anatomy, and clinical protocol. Expert consensus on embolic materials.
4. Checking blood flow
Further images assess the reduction in abnormal vascularity and confirm the remaining circulation. Treatment is tailored to your anatomy, with embolization limited to suitable target vessels. Important connections to healthy tissue may determine which branches can be treated safely. GENESIS feasibility and outcomes.
5. Recovery and discharge assessment
After catheter removal, pressure or a closure device controls bleeding at the access site. Staff monitor symptoms and circulation before discharge. Published procedural guidance describes discharge two to four hours after bleeding at the arterial access site is controlled. Procedure duration and observation time vary by case and facility. GAE procedure and discharge guidance.
What benefits and outcomes does research show?
GAE can provide meaningful pain relief and improve daily function while preserving the knee joint. Benefits reported in clinical research extend beyond pain scores to activities of daily living, recreation, and knee-related quality of life. In the prospective GENESIS study, improvements in pain, function, and quality-of-life measures remained significant at two years. GENESIS clinical outcomes.
Researchers measure benefit with pain scales and questionnaires such as WOMAC and KOOS, which assess pain, stiffness, function, and related aspects of knee health. Technical success describes completing the embolization; clinical success describes improvement in symptoms. Response rates and changes in average or median scores measure different aspects of benefit.
What do randomized trials show?
A sham procedure imitates aspects of treatment without delivering its active component. It helps researchers separate the effect of embolization from expectations, attention, and natural changes in pain.
Study | Main finding | What it means |
|---|---|---|
Bagla, 2022: 21 patients | GAE produced statistically significant improvements in pain and function over sham at one month. Bagla trial | Demonstrated benefit beyond sham at one month. The small sample, crossover, and five exclusions limit interpretation; a sensitivity analysis including excluded participants also supported improvement. |
Landers, 2023: 59 patients | No significant overall advantage over sham at 12 months. Landers trial | An exploratory complete-embolization subgroup had better sports/recreation, quality-of-life, and global-change outcomes than sham. The overall trial result remained neutral. |
van Zadelhoff, 2024: 58 patients; 2026 follow-up | Both groups improved; no statistically significant pain advantage over sham at four or 12 months. Four-month report; 12-month report | These reports concern the same trial, not two independent patient populations. |
Kumar, 2026: 50 patients | At one year, reported reduction in visual analog scale (VAS) pain scores was 72.7% with GAE plus standard care versus 24.2% with standard care. Standard-care comparison | Supports pain and functional benefits over standard care at one year. The percentages describe pain-score changes, not patient response rates; the trial did not use a sham control. |
Clinical studies, including randomized trials, have demonstrated significant pain relief and functional improvement with GAE. Results from sham-controlled trials vary, so the added benefit has not been consistent across study settings. Further research is refining patient selection, treatment technique, and estimates of long-term benefit.
What do larger and longer-term studies show?
Larger cohorts have documented sustained pain reduction and better knee-related quality of life. In a retrospective study of 333 patients, median pain decreased from 7 to 3 out of 10 at 12 months; 272 patients completed that follow-up. Median KOOS quality-of-life scores increased from 19 to 42, with higher scores indicating improvement. A separate prospective study of rapidly resorbable particles reported the same median pain decrease, from 7 to 3, with 154 of 194 patients assessed at 12 months. Both studies reported statistically significant improvements. Their observational designs and incomplete follow-up limit conclusions about the treatment-specific effect. 2025 cohort; 2026 resorbable-particle study.
Substantial benefit can persist for two years. In a prospective study, 18 of 38 assessed patients—47.4%—achieved at least 50% improvement in the total WOMAC score at two years. Among the 25 patients who had responded at one year, 18—72%—still met that threshold at two years. Seven initial responders experienced symptom recurrence. Two-year prospective outcomes.
How long does relief last, and can GAE delay knee replacement?
Pain relief can last for years. An early prospective, uncontrolled study of 72 patients involving 95 knees reported cumulative clinical success of 79.8% at three years. This supports the possibility of durable benefit, although duration varies and some patients experience recurrence or limited improvement. Okuno long-term study.
A 2026 international expert consensus identifies GAE as a potential bridge to knee replacement. Its effect on the timing or eventual need for surgery has not yet been established in comparative studies. Expert recommendations on treatment goals.
Replacement can still be performed afterward. A retrospective series of 48 arthroplasties after GAE reported four adverse events. Two wound-healing complications required additional procedures; all reported events resolved. Postsurgical follow-up records were available for only 40 of the 48 arthroplasties. Incomplete follow-up and the absence of a matched control group mean this study cannot establish that prior GAE leaves surgical risk unchanged. Arthroplasty after GAE.
How does GAE compare with other knee arthritis treatments?
Treatment | Main purpose | Consideration when discussing GAE |
|---|---|---|
Exercise, physical therapy, and weight management | Improve strength, function, and joint loading. | Can be combined with GAE to support strength, mobility, and daily function. |
Appropriate medication and joint injections | Relieve symptoms; some treatments reduce inflammation. | Discuss previous benefit, side effects, and whether an adequate trial has been completed. |
Genicular nerve radiofrequency ablation | Reduce pain signaling through targeted sensory nerves. | Targets pain-transmitting nerves; GAE targets vessels associated with inflammation. Selection depends on the source of pain and treatment goals. |
Knee replacement | Surgically address advanced structural joint disease. | Requires more extensive recovery but treats structural damage that embolization cannot repair. |
GAE | Reduce arthritis-related pain and improve function by targeting abnormal vessels associated with inflammation. | Option supported by clinical research and expert consensus after conservative care fails, including for patients deferring knee replacement or unsuitable for surgery. |
Exercise, weight reduction when appropriate, selected medications, and corticosteroid injections have established roles in osteoarthritis guidelines. Radiofrequency ablation received a conditional recommendation in the American College of Rheumatology/Arthritis Foundation guideline. Selection should reflect the source of pain, treatment goals, and medical history. ACR/Arthritis Foundation osteoarthritis guideline.
What are the risks and side effects of GAE?
GAE has a generally favorable safety profile in published studies, with most reported complications being mild and temporary. Complications can still require treatment or persist, so the physician reviews risks specific to your health, vascular anatomy, and proposed technique. Systematic review of GAE safety. Important risks include:
- Access-site problems: Bruising, bleeding, hematoma, or injury to the artery used for catheter entry.
- Skin changes: Temporary redness or discoloration; unintended embolization can also cause skin ulceration.
- Pain flare: Knee discomfort may temporarily increase after treatment.
- Nerve or bone injury: Reduced blood supply to healthy structures can cause altered sensation or ischemic changes.
- Other procedural risks: Infection, contrast reactions, kidney-related concerns, and sedation complications require individualized assessment. GAE also involves exposure to X-ray radiation. Catheter embolization risks.
An early 40-patient study reported seven small superficial skin ulcers and two asymptomatic focal bone infarcts on MRI. Skin lesions healed, and protective technique changes were associated with fewer skin problems later in the series. These figures describe that protocol, not a universal complication rate. Prospective GAE safety study.
A larger prospective study using rapidly resorbable particles reported temporary skin discoloration after 15 of 239 procedures, about 6.3%, and no moderate or severe adverse events. All reported skin discoloration resolved within 24 hours. These results describe that material and protocol; differences between separate studies do not establish which material is safest. Resorbable-particle safety results.
In the Dutch sham-controlled trial, two GAE recipients developed ankle tingling or altered sensation; one case remained at 12 months. Discuss the potential for persistent symptoms and the measures used to protect normal tissue with your physician. Randomized trial safety follow-up.
Recovery after genicular artery embolization
Immediately afterward
GAE can be performed as a same-day procedure, allowing recovery at home after observation. Some study protocols include an overnight stay. The team checks your condition and access site before discharge and provides instructions for medicines, activity, and follow-up. Same-day discharge guidance; Study with overnight observation.
At home and returning to activity
Recovery involves caring for the small access site and gradually returning to activity. Published procedural guidance advises avoiding heavy lifting or vigorous activity for the first week, then increasing activity gradually. Access-site soreness, bruising, or a temporary increase in knee pain can occur; knee pain and stiffness may worsen during the first two weeks. Follow your team’s individual instructions for work, exercise, and driving. Postprocedure care for joint embolization.
As pain improves, exercise and rehabilitation can help build strength and support a return to daily activities. Track changes in the activities that matter to you, along with pain scores and medication use. Follow-up over weeks and months helps assess your progress and guide continuing care.
When to seek help
Contact your treatment team promptly for worsening pain, fever, increasing swelling, skin breakdown, new numbness, or concerns about the access site. Follow the urgent instructions provided at discharge. GAE-specific home-care guidance.
Seek emergency care for bleeding that will not stop, chest pain, difficulty breathing, fainting, or sudden weakness or trouble speaking. These are emergency warning signs regardless of which procedure you have had. Recognizing medical emergencies.
Frequently asked questions
Is GAE painful?
Local anesthetic numbs the access site, and sedation may be offered to help you remain comfortable. The team will discuss pain control during the procedure and recovery. Temporary soreness or a knee-pain flare can occur afterward.
Is GAE the same as a genicular nerve block?
No. GAE targets blood vessels. A nerve block uses an injection to temporarily interrupt pain signals; radiofrequency ablation targets sensory nerves for a longer-lasting effect. Similar names do not mean the treatments are interchangeable.
Is GAE an accepted treatment?
GAE is a clinically used treatment with published evidence of pain relief and functional improvement. A 2026 international expert consensus supports considering it for appropriately selected patients after conservative treatment has failed. Recommendations vary across organizations. NICE’s guidance, originating in 2021, continues to recommend use within research because of uncertainty about efficacy and long-term safety. International expert recommendations; NICE guidance.
Is GAE FDA-approved?
Clinical evidence and FDA device labeling address different questions. A 2026 expert consensus article reported that the embolic agents discussed for GAE remained off-label for this use in the United States at publication. FDA Breakthrough Device designation is distinct from marketing authorization. Ask about the specific product and its current status. Academic review of embolic-agent regulation; FDA Breakthrough Devices Program.
Does insurance cover GAE?
Coverage depends on the plan, indication, and authorization requirements. Ask your practice and insurer to confirm coverage and expected professional, facility, and follow-up charges before scheduling. Coverage policies can differ from professional-society recommendations: Aetna’s Clinical Policy Bulletin 0856, for example, lists GAE for osteoarthritis-related knee pain as experimental, investigational, or unproven. Aetna GAE coverage policy.
Can GAE treat pain after knee replacement?
GAE has also shown promising pain relief in patients with persistent symptoms after knee replacement. A 16-patient retrospective study reported pain improvement. Before considering treatment, the team evaluates infection, implant loosening, and other mechanical causes. Evidence for this application is smaller than the evidence base for osteoarthritis in a knee that has not been replaced. GAE for persistent pain after arthroplasty; Patient selection after arthroplasty.
Find a physician to discuss GAE
The Outpatient Endovascular and Interventional Society provides patient resources about minimally invasive care. Use the OEIS Find a Physician directory to search by procedure, specialty, and location, then contact the practice to discuss your symptoms and available options.
If knee arthritis pain persists despite physical therapy, medication, or injections, a consultation can help determine whether GAE fits your treatment goals. Bring your imaging and treatment history, and discuss expected pain relief, activity goals, alternatives, and the follow-up plan.
This resource provides general education. Your treating physician can explain how the evidence and risks apply to your medical history and proposed treatment.
